product
Pritelivir (Hovilpri)
Also known as Hovilpri
Pritelivir, sold as Hovilpri, was approved by the FDA on 9 October 2026 for adults with weakened immune systems whose herpes simplex virus (HSV) skin or mucous membrane lesions have not responded to other therapies.[1] It is an oral helicase-primase inhibitor, a different mechanism from standard herpes drugs.[2] Its developer, AiCuris, reported that lesions healed in 62.7% of patients on pritelivir versus 34.0% on standard treatment in its pivotal phase 3 trial.[3]
Key facts
Pritelivir is an oral antiviral against herpes simplex virus (HSV). It works as a helicase-primase inhibitor, a different mechanism from standard drugs such as acyclovir.[2] On 9 October 2026 the FDA approved it as Hovilpri for adults with weakened immune systems who have HSV lesions of the skin or mucous membranes that have not responded to other therapies.[1]
This page is not medical advice. Anyone with a weakened immune system and a herpes infection should talk to their doctor.
Why it matters
People with weakened immune systems are at risk of severe, prolonged herpes recurrences. Infections that resist treatment, and intolerance of standard therapy, leave an unmet need.[4]
Trial evidence
The developer, AiCuris, reported in February 2026 that in its pivotal phase 3 trial pritelivir healed lesions in 62.7% of immunocompromised patients with refractory HSV, against 34.0% with the investigator’s choice of standard treatment. It also reported fewer treatment-emergent adverse events.[3] These figures come from the company.[3]
A peer-reviewed paper published in August 2026 described a randomized, open-label phase 2 PRIOH-1 study. It compared oral pritelivir with intravenous foscarnet for up to 28 days in immunocompromised adults with acyclovir-refractory HSV.[5] In its main part, with 22 participants, healing rates were 93% with pritelivir and 57% with foscarnet. That difference was not statistically significant. Treatment-emergent adverse events occurred in 60% of pritelivir and 100% of foscarnet recipients.[6]
Path to approval
In April 2026 AiCuris announced that the FDA had granted Priority Review to its application for pritelivir.[7] The FDA approved it on 9 October 2026.[1] In February 2026 AiCuris agreed to be acquired by Asahi Kasei, through its US subsidiary Veloxis Pharmaceuticals, for 780 million euros (about $920 million).[8] For background on the process, see how FDA drug approval works.
Read next
Health in 2026: a crash course
How drugs are tested and approved, who regulates them, and where to start on cholesterol, diabetes, dementia, ALS and cancer screening.
Questions readers ask
What is pritelivir approved for?
Treating adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus that have not responded to other therapies. The FDA approved it on 9 October 2026.[1]
How is it different from acyclovir?
It is a helicase-primase inhibitor, which attacks the virus in a different way from standard antivirals.[2]
Why do immunocompromised people need it?
They are at risk of severe, prolonged herpes recurrences, and refractory disease and intolerance of standard drugs leave an unmet need.[4]
What did the trials show?
AiCuris reported 62.7% lesion healing with pritelivir versus 34.0% with the investigator's choice of standard treatment in its pivotal phase 3 trial. A smaller published comparison with foscarnet found healing rates of 93% versus 57%, a difference that was not statistically significant.[3][6]
Sources
· 8 claims from 3 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
On 9 October 2026 the FDA approved Hovilpri (pritelivir) to treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus (HSV) infection that have not responded to other therapies. confirmedas of 2026-10-09
- Novel Drug Approvals for 2026 · US Food and Drug Administration · Primary source · Row 46, Hovilpri, 10/9/2026 (retrieved 2026-11-14)
- [2]
Pritelivir is an oral HSV helicase-primase inhibitor, a different mechanism from standard antiviral drugs such as acyclovir. confirmedas of 2026-08-31
- Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial (Kotton et al., Open Forum Infect Dis 2026): abstract · Open Forum Infectious Diseases (abstract via NCBI PubMed) · Primary source · 2026-08-31 (retrieved 2026-11-14)
- [3]
The developer, AiCuris, reported in February 2026 that in its pivotal phase 3 trial pritelivir achieved lesion healing in 62.7% of immunocompromised patients with refractory HSV, compared with 34.0% for the investigator's choice of standard treatment, with fewer treatment-emergent adverse events. confirmedas of 2026-02-05
- News and events · AiCuris Anti-infective Cures AG · Primary source · 2026-02-05 news item (retrieved 2026-11-14)
- [4]
Immunocompromised people are at risk of severe, prolonged HSV recurrences, and refractory disease and intolerance to standard therapy leave an unmet need. confirmedas of 2026-08-31
- Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial (Kotton et al., Open Forum Infect Dis 2026): abstract · Open Forum Infectious Diseases (abstract via NCBI PubMed) · Primary source · 2026-08-31 (retrieved 2026-11-14)
- [5]
A trial published in Open Forum Infectious Diseases in August 2026, described there as the randomized, open-label phase 2 PRIOH-1 study, compared oral pritelivir with intravenous foscarnet for up to 28 days in immunocompromised adults with acyclovir-refractory HSV. confirmedas of 2026-08-31
- Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial (Kotton et al., Open Forum Infect Dis 2026): abstract · Open Forum Infectious Diseases (abstract via NCBI PubMed) · Primary source · 2026-08-31 (retrieved 2026-11-14)
- Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial (Kotton et al., Open Forum Infect Dis 2026): abstract · Open Forum Infectious Diseases (abstract via NCBI PubMed) · Primary source · 2026-08-31 (retrieved 2026-11-14)
- [6]
In that trial's main part (22 participants), investigator-assessed healing rates were 93% with pritelivir and 57% with foscarnet, a difference that was not statistically significant (P = .077), and treatment-emergent adverse events occurred in 60% of pritelivir and 100% of foscarnet recipients. confirmedas of 2026-08-31
- Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial (Kotton et al., Open Forum Infect Dis 2026): abstract · Open Forum Infectious Diseases (abstract via NCBI PubMed) · Primary source · 2026-08-31 (retrieved 2026-11-14)
- Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial (Kotton et al., Open Forum Infect Dis 2026): abstract · Open Forum Infectious Diseases (abstract via NCBI PubMed) · Primary source · 2026-08-31 (retrieved 2026-11-14)
- [7]
In April 2026 AiCuris announced that the FDA had granted Priority Review to its new drug application for pritelivir. confirmedas of 2026-04-16
- News and events · AiCuris Anti-infective Cures AG · Primary source · 2026-04-16 news item (retrieved 2026-11-14)
- [8]
In February 2026 AiCuris agreed to be acquired by Asahi Kasei, through its US subsidiary Veloxis Pharmaceuticals, for a total of 780 million euros (about $920 million). confirmedas of 2026-02-26
- News and events · AiCuris Anti-infective Cures AG · Primary source · 2026-02-26 news item (retrieved 2026-11-14)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 14, 2027.
Cite this page
"Pritelivir (Hovilpri)." ContentLora, updated Nov 14, 2026. https://contentlora.com/wiki/pritelivir
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.